Skip to main content

Table 2 Univariate analyses of factors by cox regression model associated with recurrence-free survival (RFS) in test and validation cohort (*, P < 0.05; **, P < 0.01)

From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

 

Test cohort

 

Validation cohort

 

Variable

RFS hazard ratio (95% Cl)

Pvalue

RFS hazard ratio (95% Cl)

Pvalue

Age (≤50, > 50)

0.463 (0.178-1.206)

0.115

3.673 (1.126-11.983)

0.031*

Gender (male, female)

0.594 (0.237-1.489)

0.266

0.342 (0.161-0.728)

0.005**

Tumor site (stomach, no stomach)

9.629 (2.820-32.879)

<0.001**

1.760 (0.900-3.440)

0.098

Tumor size (≤10, > 10 cm)

8.732 (3.604-21.154)

<0.001**

5.392 (2.787-10.430)

<0.001**

Mitosis count (≤10, > 10/50 HPF)

13.459 (5.470-33.115)

<0.001**

8.462 (4.335-16.519)

<0.001**

Serosal invasion (Yes, No)

20.531 (8.170-51.596)

<0.001**

7.706 (3.938-15.081)

<0.001**